Background :This study was conducted to evaluate the efficacy and safety of 200 μg misoprostol administered vaginally every 4 hours to a maximum of 48 hours for second trimester intrauterine fetal death. Methods: We conducted a prospective, randomized trial comparing the efficacy and safety of misorostol either in its dry form (group A) or moistened with 1 ml saline (group B). The study population included 136 pregnant women between 14 and 24 weeks gestation who were seeking for termination of pregnancy because of intrauterine fetal death. Setting: Woman’s Health Center, Assiut University Hospitals. Results: All patients in both groups aborted within 48 hours (100% success rate), the median induction-abortion interval was significantly shorter in group B than in group A (p0.01) patients in group B had significantly short median induction-abortion interval(p0.01) , less total number of doses (p0.05) , less retained placenta ((p0.05), more aborton within 24 hours (p0.01), more aborton with the 1st dose(p0.01) but had more need for analgesia and more incidence of side effects (p0.01). Conclusion: The intravaginal administration of 200 μg misoprostol tablets moistened with saline every 4 hours was effective for second trimester pregnancy termination and superior to dry misoprostol tablets. However it was associated with more side effects whisch were well tolerated.

Background :This study was conducted to evaluate the efficacy and safety of 200 μg misoprostol administered vaginally every 4 hours to a maximum of 48 hours for second trimester intrauterine fetal death. Methods: We conducted a prospective, randomized trial comparing the efficacy and safety of misorostol either in its dry form (group A) or moistened with 1 ml saline (group B). The study population included 136 pregnant women between 14 and 24 weeks gestation who were seeking for termination of pregnancy because of intrauterine fetal death. Setting: Woman’s Health Center, Assiut University Hospitals. Results: All patients in both groups aborted within 48 hours (100% success rate), the median induction-abortion interval was significantly shorter in group B than in group A (p0.01) patients in group B had significantly short median induction-abortion interval(p0.01) , less total number of doses (p0.05) , less retained placenta ((p0.05), more aborton within 24 hours (p0.01), more aborton with the 1st dose(p0.01) but had more need for analgesia and more incidence of side effects (p0.01). Conclusion: The intravaginal administration of 200 μg misoprostol tablets moistened with saline every 4 hours was effective for second trimester pregnancy termination and superior to dry misoprostol tablets. However it was associated with more side effects whisch were well tolerated.

Objectives: To compare the efficacy of two different techniques for cervical ripening and labour induction in early third trimester pregnancy.Study design: This is a randomized controlled clinical trial. Two hundred pregnant women in early third trimester were enrolled in the study. They had either intrauterine fetal death or severe preeclampsia which necessitated pregnancy termination but patients refused cesarean delivery due to low chance of postnatal survival. Subjects were randomized into two groups: in group 1: an Intrauterine Foley catheter was inserted plus 4 doses of misoprostol 50μg every 6 hours. In group 2: Misoprostol only was administered in a dose of 50μ every 6 hours Results: There was significant shortening of the interval from induction to establishment of active phase in nulliparous women in the first group (P=0.003) with significant reduction of induction to delivery time interval in both nulliparous and multiparous women in the same group more than that in the misoprostol group (P=0.006 and 0.001 respectively). The number of cesarean deliveries due to failed induction were significantly reduced in the first group among nulliparous women (P=0.02) in comparison to group 2. There were no cases of chorioamnionitis or postpartum endometritis in women used Intrauterine Foley catheter. Conclusion: A combination of Intrauterine Foley catheter plus misoprostol was more effective than misoprostol alone in cervical ripening and labour induction in early third trimester pregnancy

Changes in insulin structure may alter the way it interacts with insulin and insulin-like growth factor-1 receptors. Possible associations between the use of the long-acting insulin analog, glargine, and an increased risk of cancer have been widely examined. Strong evidence indicates a role for exogenous insulin or analogs in promoting cancer growth in diabetic patients. The clinical relevance of this pro-cancer effect of insulin in diabetic patients, however, is still unclear. In this study, the genotoxic and cytotoxic potential of insulin glargine (5, 12.5 and 25I.U/kg, S.C. daily for 2 weeks) was evaluated against the nicotinamide (NA-230mg/kg) and streptozotocin (STZ-65mg/kg) induced somatic and germinal cells defect using a battery of in vivo cytogenetic assays such as the micronucleus, chromosome aberration, mitotic index and sperm abnormality test in male Wistar rats. The obtained results demonstrated that insulin glargine significantly reduced the diabetes-induced genetic damage and cell proliferation changes in somatic cells. Moreover, the administration of insulin glargine reduced the diabetes-induced genetic damage in germinal cells. The results suggest that insulin glargine is not genotoxic or cytotoxic compound and its use does not present a carcinogenic risk.

Changes in insulin structure may alter the way it interacts with insulin and insulin-like growth factor-1 receptors. Possible associations between the use of the long-acting insulin analog, glargine, and an increased risk of cancer have been widely examined. Strong evidence indicates a role for exogenous insulin or analogs in promoting cancer growth in diabetic patients. The clinical relevance of this pro-cancer effect of insulin in diabetic patients, however, is still unclear. In this study, the genotoxic and cytotoxic potential of insulin glargine (5, 12.5 and 25I.U/kg, S.C. daily for 2 weeks) was evaluated against the nicotinamide (NA-230mg/kg) and streptozotocin (STZ-65mg/kg) induced somatic and germinal cells defect using a battery of in vivo cytogenetic assays such as the micronucleus, chromosome aberration, mitotic index and sperm abnormality test in male Wistar rats. The obtained results demonstrated that insulin glargine significantly reduced the diabetes-induced genetic damage and cell proliferation changes in somatic cells. Moreover, the administration of insulin glargine reduced the diabetes-induced genetic damage in germinal cells. The results suggest that insulin glargine is not genotoxic or cytotoxic compound and its use does not present a carcinogenic risk.

Changes in insulin structure may alter the way it interacts with insulin and insulin-like growth factor-1 receptors. Possible associations between the use of the long-acting insulin analog, glargine, and an increased risk of cancer have been widely examined. Strong evidence indicates a role for exogenous insulin or analogs in promoting cancer growth in diabetic patients. The clinical relevance of this pro-cancer effect of insulin in diabetic patients, however, is still unclear. In this study, the genotoxic and cytotoxic potential of insulin glargine (5, 12.5 and 25I.U/kg, S.C. daily for 2 weeks) was evaluated against the nicotinamide (NA-230mg/kg) and streptozotocin (STZ-65mg/kg) induced somatic and germinal cells defect using a battery of in vivo cytogenetic assays such as the micronucleus, chromosome aberration, mitotic index and sperm abnormality test in male Wistar rats. The obtained results demonstrated that insulin glargine significantly reduced the diabetes-induced genetic damage and cell proliferation changes in somatic cells. Moreover, the administration of insulin glargine reduced the diabetes-induced genetic damage in germinal cells. The results suggest that insulin glargine is not genotoxic or cytotoxic compound and its use does not present a carcinogenic risk.

Changes in insulin structure may alter the way it interacts with insulin and insulin-like growth factor-1 receptors. Possible associations between the use of the long-acting insulin analog, glargine, and an increased risk of cancer have been widely examined. Strong evidence indicates a role for exogenous insulin or analogs in promoting cancer growth in diabetic patients. The clinical relevance of this pro-cancer effect of insulin in diabetic patients, however, is still unclear. In this study, the genotoxic and cytotoxic potential of insulin glargine (5, 12.5 and 25I.U/kg, S.C. daily for 2 weeks) was evaluated against the nicotinamide (NA-230mg/kg) and streptozotocin (STZ-65mg/kg) induced somatic and germinal cells defect using a battery of in vivo cytogenetic assays such as the micronucleus, chromosome aberration, mitotic index and sperm abnormality test in male Wistar rats. The obtained results demonstrated that insulin glargine significantly reduced the diabetes-induced genetic damage and cell proliferation changes in somatic cells. Moreover, the administration of insulin glargine reduced the diabetes-induced genetic damage in germinal cells. The results suggest that insulin glargine is not genotoxic or cytotoxic compound and its use does not present a carcinogenic risk.

Changes in insulin structure may alter the way it interacts with insulin and insulin-like growth factor-1 receptors. Possible associations between the use of the long-acting insulin analog, glargine, and an increased risk of cancer have been widely examined. Strong evidence indicates a role for exogenous insulin or analogs in promoting cancer growth in diabetic patients. The clinical relevance of this pro-cancer effect of insulin in diabetic patients, however, is still unclear. In this study, the genotoxic and cytotoxic potential of insulin glargine (5, 12.5 and 25I.U/kg, S.C. daily for 2 weeks) was evaluated against the nicotinamide (NA-230mg/kg) and streptozotocin (STZ-65mg/kg) induced somatic and germinal cells defect using a battery of in vivo cytogenetic assays such as the micronucleus, chromosome aberration, mitotic index and sperm abnormality test in male Wistar rats. The obtained results demonstrated that insulin glargine significantly reduced the diabetes-induced genetic damage and cell proliferation changes in somatic cells. Moreover, the administration of insulin glargine reduced the diabetes-induced genetic damage in germinal cells. The results suggest that insulin glargine is not genotoxic or cytotoxic compound and its use does not present a carcinogenic risk.

Changes in insulin structure may alter the way it interacts with insulin and insulin-like growth factor-1 receptors. Possible associations between the use of the long-acting insulin analog, glargine, and an increased risk of cancer have been widely examined. Strong evidence indicates a role for exogenous insulin or analogs in promoting cancer growth in diabetic patients. The clinical relevance of this pro-cancer effect of insulin in diabetic patients, however, is still unclear. In this study, the genotoxic and cytotoxic potential of insulin glargine (5, 12.5 and 25I.U/kg, S.C. daily for 2 weeks) was evaluated against the nicotinamide (NA-230mg/kg) and streptozotocin (STZ-65mg/kg) induced somatic and germinal cells defect using a battery of in vivo cytogenetic assays such as the micronucleus, chromosome aberration, mitotic index and sperm abnormality test in male Wistar rats. The obtained results demonstrated that insulin glargine significantly reduced the diabetes-induced genetic damage and cell proliferation changes in somatic cells. Moreover, the administration of insulin glargine reduced the diabetes-induced genetic damage in germinal cells. The results suggest that insulin glargine is not genotoxic or cytotoxic compound and its use does not present a carcinogenic risk.

NULL